摘要
目的探讨高通量血液透析联合左卡尼汀治疗尿毒症心肌病患者临床效果。方法选择2016年2月—2017年11月尿毒症心肌病患者90例作为研究对象。根据治疗方法的不同,将其分为两组。对照组给予单一高通量血液透析治疗,观察组则给予高通量血液透析联合左卡尼汀治疗。比较两组尿毒症心肌病治疗总有效率;心肌病纠正时间;治疗后患者射血分数、白蛋白、红细胞计数、血红蛋白;副作用。结果观察组尿毒症心肌病治疗总有效率高于对照组、纠正时间、生化指标等优于对照组,差异具有统计学意义(P <0.05)。两组无明显副作用,组间对比,差异无统计学意义(P> 0.05)。结论高通量血液透析联合左卡尼汀治疗尿毒症心肌病的应用效果确切。
Objective To investigate the clinical effect of high-dose hemodialysis combined with L-carnitine in the treatment of uremic cardiomyopathy. Methods 90 patients with uremic cardiomyopathy from February 2016 to November 2017 were selected as the subjects. According to the different treatment methods, they were divided into two groups. The control group was treated with single high fux hemodialysis. The observation group was given high flux hemodialysis combined with levocarnitine treatment. The total effective rate, cardiomyopathy correction time, ejection fraction, albumin, red blood cell count, hemoglobin and side effects were compared between the two groups. Results The total effective rate of uremic cardiomyopathy in the observation group was higher than that in the control group, the correction time and biochemical indexes were better than those in the control group, and the difference was statistically significant （P 〈 0.05）. There was no significant side effect between the two groups, and there was no signifcant difference between the two groups （P 〉 0.05）. Conclusion The effect of high-fux hemodialysis combined with L-carnitine in the treatment of uremic cardiomyopathy is exact.
作者
董权
DONG Quan(Department of Cardiology,Yunyang District People＇s Hospital of Shiyan City,Shiyan Hubei 442500,China)
出处
《中国继续医学教育》
2018年第28期121-123,共3页
China Continuing Medical Education
